A Phase I Study to Investigate the Effect of Hepatic Impairment on the� PK, Safety, and Tolerability of AZD2693

Trial Identifier:	D7830C00008
Sponsor:	AstraZeneca
NCTID::	NCT05919069
Start Date:	June 2023
Primary Completion Date:	September 2024
Study Completion Date:	September 2024
Condition:	Liver, Pancreas & Gallbladder - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description
	English Version

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
US, CA	Rialto, CA, US, 92377
US, FL	Miami Lakes, FL, US, 33014
US, FL	Orlando, FL, US, 32808

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.